Asunto(s)
Citarabina/efectos adversos , Paraplejía/inducido químicamente , Enfermedad Aguda , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Burkitt/complicaciones , Linfoma de Burkitt/tratamiento farmacológico , Citarabina/administración & dosificación , Humanos , Inyecciones Espinales , Masculino , Persona de Mediana EdadRESUMEN
Nineteen patients with locoregional non-small-cell lung cancer (NSCLC) were treated with two courses of cisplatin/VP-16/MGBG, followed by involved field radiotherapy and, subsequently, the same chemotherapy alternating with mitomycin-C/vinblastine. Five of 17 patients obtained a response (CR + PR) after induction chemotherapy. Following radiotherapy, an additional two patients responded. The median survival was 7.5 months, with the two longest survivors at 30 and 32 months. Hematologic toxicity was severe, with two deaths from severe neutropenia. Renal and gastrointestinal toxicities were moderate. This program of aggressive therapy did not increase the response rate or median survival compared with those of comparable patients treated in recent trials using radiotherapy alone or combined radiotherapy plus chemotherapy.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Cisplatino/administración & dosificación , Cisplatino/efectos adversos , Terapia Combinada , Evaluación de Medicamentos , Etopósido/administración & dosificación , Etopósido/efectos adversos , Femenino , Humanos , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/radioterapia , Masculino , Persona de Mediana Edad , Mitoguazona/administración & dosificación , Mitoguazona/efectos adversos , Mitomicinas/administración & dosificación , Mitomicinas/efectos adversos , Vinblastina/administración & dosificación , Vinblastina/efectos adversosRESUMEN
This syndrome should be suspected in patients with clinical features of lymphadenopathy, hepatosplenomegaly, hypercalcemia, bone lesions and circulating lymphocytes with pleomorphic nuclei. Most biopsy material has morphologic characteristics of intermediate or high-grade non-Hodgkins lymphoma. Antibody titers to human T-lymphotropic virus type I confirm the diagnosis. Treatment with combination chemotherapy results in remission for most patients, but duration of response is usually short.